![Jan Mikkelsen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jan Mikkelsen
Founder at
ASCENDIS PHARMA A/S
Net worth: 102 M $ as of 31/05/2026
Profile
Mr. Jan M. Mikkelsen is a Chief Executive Officer & Director at Ascendis Pharma Endocrinology Division A/S, a President, CEO & Executive Director at Ascendis Pharma A/S, a Chief Executive Officer at Ascendis Pharma Bone Diseases A/S and a Chief Executive Officer at Ascendis Pharma Growth Disorders AS. He is on the Board of Directors at Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma A/S and Visen Pharmaceuticals (Shanghai) Co. Ltd. Mr. Mikkelsen was previously employed as a President & Chief Executive Officer by LifeCycle Pharma A/S, a President-Pharmaceutical Division by Maxygen, Inc., a Co-Chief Executive Officer by Profound Pharma AS, and a Vice President-Protein Discovery by Novo Nordisk A/S. He received his undergraduate degree from the University of Southern Denmark.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ASCENDIS PHARMA A/S -.--% | 18/03/2026 | 453,403 ( -.--% ) | 102 M $ | 31/05/2026 |
Latest news about Jan Mikkelsen
Jan Mikkelsen active positions
| Companies | Position | Start |
|---|---|---|
| ASCENDIS PHARMA A/S | Founder | 21/09/2006 |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Manufactures endocrine pharmaceutical products | Chief Executive Officer | 29/06/2012 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Director/Board Member | - |
Ascendis Pharma Bone Diseases A/S | Chief Executive Officer | - |
Ascendis Pharma Growth Disorders AS | Chief Executive Officer | - |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Consultant / Advisor | 01/01/2022 |
Hummingbird Bioscience Holdings Pte Ltd.
 Hummingbird Bioscience Holdings Pte Ltd. MiscellaneousMiscellaneous Functions as an investment holding company | Chairman | 01/01/2021 |
Former positions of Jan Mikkelsen
| Companies | Position | End |
|---|---|---|
| VISEN PHARMACEUTICALS | Director/Board Member | 27/06/2025 |
| VELOXIS PHARMACEUTICALS A/S | Chief Executive Officer | 01/01/2006 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Jan Mikkelsen
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
65
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Finance |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
University of Southern Denmark
 University of Southern Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Manufactures endocrine pharmaceutical products | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Health Technology |
Ascendis Pharma Bone Diseases A/S | |
Hummingbird Bioscience Holdings Pte Ltd.
Hummingbird Bioscience Holdings Pte Ltd. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Ascendis Pharma Growth Disorders AS | |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
- Stock Market
- Insiders
- Jan Mikkelsen
